Prognostic impact of CD168 expression in gastric cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Ishigami, Sumiya ^a   Ueno, Shinichi ^a   Nishizono, Yuka ^a   Matsumoto, Masataka ^a   Kurahara, Hiroshi ^a   Arigami, Takaaki ^a   Uchikado, Yasuto ^a   Setoyama, Tetsuro ^a   Arima, Hideo ^a   Yoshiaki, Kita ^a   Kijima, Yuko ^a   Kitazono, Masaki ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD168 ANTIGEN; HYALURONIC ACID; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; HERMES ANTIGEN; HYALURONAN MEDIATED MOTILITY RECEPTOR; HYALURONAN-MEDIATED MOTILITY RECEPTOR; SCLEROPROTEIN; TUMOR MARKER;

ADULT; AGE; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; PROGNOSIS; SEX DIFFERENCE; STOMACH CANCER; CARCINOMA; DISEASE COURSE; GENETICS; IMMUNOCHEMISTRY; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; STOMACH TUMOR; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CARCINOMA; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; HYALURONIC ACID; IMMUNOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953112809     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-106     Document Type: Article

References (22)

1. Yeo TK, Nagy JA, Yeo KT, Dvorak HF, Toole BP. Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol 1996, 148:1733-40. 1861653, 8669459.
2. Yamada Y, Itano N, Narimatsu H, Kudo T, Hirohashi S, Ochiai A, Niimi A, Ueda M, Kimata K. Receptor for hyaluronan-mediated motility and CD44 expressions in colon cancer assessed by quantitative analysis using real-time reverse transcriptase-polymerase chain reaction. Jpn J Cancer Res 1999, 90:987-92.
3. Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci 1998, 111:1685-94.
4. Turley EA, Moore D, Hayden LJ. Characterization of hyaluronate binding proteins isolated from 3T3 and murine sarcoma virus transformed 3T3 cells. Biochemistry 1987, 26:2997-3005. 10.1021/bi00385a007, 2440472.
5. Yamano Y, Uzawa K, Shinozuka K, Fushimi K, Ishigami T, Nomura H, Ogawara K, Shiiba M, Yokoe H, Tanzawa H. Hyaluronan-mediated motility: a target in oral squamous cell carcinoma. Int J Oncol 2008, 32:1001-9.
6. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J, Turley EA. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007, 282:16667-80. 10.1074/jbc.M702078200, 2949353, 17392272.
7. Knüpfer MM, Poppenborg H, Hotfilder M, Kühnel K, Wolff JE, Domula M. CD44 expression and hyaluronic acid binding of malignant glioma cells. Clin Exp Metastasis 1999, 17:71-6.
8. Assmann V, Gillett CE, Poulsom R, Ryder K, Hart IR, Hanby AM. The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behavior of tumour cells. J Pathol 2001, 195:191-6. 10.1002/path.941, 11592098.
9. Wang C, Thor AD, Moore DH, Zhao Y, Kerschmann R, Stern R, Watson PH, Turley EA. The overexpression of RHAMM, a hyaluronan -binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 1998, 4:567-76.
10. Kong QY, Liu J, Chen XY, Wang XW, Sun Y, Li H. Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder. Oncol Rep 2003, 10:51-5.
11. Rein DT, Roehrig K, Schöndorf T, Lazar A, Fleisch M, Niederacher D, Bender HG, Dall PJ. Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis. Cancer Res Clin Oncol 2003, 129:161-4.
12. Japanese Gastric Cancer Association Japanese Classification of Gastric Carcinoma. Gastric Cancer 1998, 1:10-24. 2, Japanese Gastric Cancer Association.
13. Zlobec I, Baker K, Terracciano L, Peter S, Degen L, Beglinger C, Lugli A. Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer 2008, 99:1712-7. 10.1038/sj.bjc.6604729, 18985041.
14. Abetamann V, Kern HF, Elsässer HP. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res 1996, 2:1607-18.
15. Li H, Guo L, Li JW, Liu N, Qi R, Liu J. Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression. Int J Oncol 2000, 17:927-32.
16. Sohr S, Engeland K. Cell Cycle 2008, 7:3448-60. 10.4161/cc.7.21.7014, 18971636.
17. Lugli A, Zlobec I, Günthert U, Minoo P, Baker K, Tornillo L, Terracciano L, Jass JR. Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Mod Pathol 2006, (10):1302-9. 10.1038/modpathol.3800648, 16763611.
18. Zlobec I, Baker K, Terracciano LM, Lugli A. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res 2008, 14:3798-806. 10.1158/1078-0432.CCR-07-5103, 18559599.
19. Zlobec I, Baker K, Terracciano L, Peter S, Degen L, Beglinger C, Lugli A. Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer 2008, 99:1712-7. 10.1038/sj.bjc.6604729, 2584947, 18985041.
20. Assmann V, Gillett CE, Poulsom R, Ryder K, Hart IR, Hanby AM. The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behavior of tumour cells. J Pathol 2001, 195:191-6. 10.1002/path.941, 11592098.
21. Filling the mosaic of p53 actions: p53 represses RHAMM expression Cell Cycle. 2008, 7:3479.
22. Lin SL, Chang D, Chiang A, Ying SY. Androgen receptor regulates CD168 expression and signaling in prostate cancer. Carcinogenesis 2008, 29:282-90. 10.1093/carcin/bgm259, 18174258.